VSE knjižnice (vzajemna bibliografsko-kataložna baza podatkov COBIB.SI)
-
Naše izkušnje zdravljenja kronične mieloične levkemije z imatinib mesilatom = Our experience with treatment of chronic myeloid leukemia with imatinib mesylateModic, Mojca, 1954- ; Sever, Matjaž, 1976-Background. Imatinib mesylate is an Abl kinase inhibitor capable of producing a sustained complete molecular response in chronic myelogenous leukemia (CML).It is effective in all three phases of CML ... with the longest response in the chronic phase. Imatinib has been in use only since 1998 and many questionsabout its efficacy and use are still unanswered. Methods and results.From October 2001 until January 2004 thirty-one patients with CML havebeen treated with imatinib (300-600 mg/day) at our institution. Twelve patients were in chronic phase of CML, 23 in accelerated phase and 3 in blast crisis. Two were treated after unrelated peripheral blood stem, cell transplantation (PBSCT) due to CML reactivation. All had been treated prior toinstituting imatinib (hydroxiurea, interferon - alpha, cytarabine). Completecytogenetic respovase (CCR) in patients in chronic phase occured in 33.3% and complete molecular response (CMR) occured in 41.7%. CCR in patients in accelerated phase occured in 30.8% and CMR occured in 46.2%. None of the patients in blast crisis had CCR or CMR. Several side effects were reported during the treatment However, among them there was not the most common side effect reported in other studies. Limb muscle and bone pains (20%) were the most frequently reported side effects in our group of patients. Conclusions. Imatinib has be found to be most effective in chronic and accelerated phase ofCML. However, there is still not enough data about its long-term use and prognosis. For the time being PBSCT remains the only proven curative treatmentof CML.Vir: Številka ob 2. kongresu hematologov in transfuziologov Slovenije z mednarodno udeležbo (str. I-27-I-30)Vrsta gradiva - prispevek na konferenci ; neleposlovje za odrasleLeto - 2004Jezik - slovenskiCOBISS.SI-ID - 17679065
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|---|
Modic, Mojca, 1954- | 23819 |
Sever, Matjaž, 1976- | 24908 |
Vir: Osebne bibliografije
in: SICRIS
Izberite prevzemno mesto:
Prevzem gradiva po pošti
Naslov za dostavo:
Med podatki člana manjka naslov.
Storitev za pridobivanje naslova trenutno ni dostopna, prosimo, poskusite še enkrat.
S klikom na gumb "V redu" boste potrdili zgoraj izbrano prevzemno mesto in dokončali postopek rezervacije.
S klikom na gumb "V redu" boste potrdili zgoraj izbrano prevzemno mesto in naslov za dostavo ter dokončali postopek rezervacije.
S klikom na gumb "V redu" boste potrdili zgoraj izbrani naslov za dostavo in dokončali postopek rezervacije.
Obvestilo
Trenutno je storitev za avtomatsko prijavo in rezervacijo nedostopna. Gradivo lahko rezervirate sami na portalu Biblos ali ponovno poskusite tukaj kasneje.
Gesla v Splošnem geslovniku COBISS
Izbira mesta prevzema
Gradivo iz matične enote je brezplačno. Če je gradivo na mesto prevzema dostavljeno iz drugih enot, lahko knjižnica to storitev zaračuna.
Mesto prevzema | Status gradiva | Rezervacija |
---|
Rezervacija v teku
Prosimo, počakajte trenutek.
Rezervacija je uspela.
Rezervacija ni uspela.
Rezervacija...
Članska izkaznica:
Mesto prevzema: